FREMONT, Calif., Sept. 22, 2016
FREMONT, Calif., Sept. 22, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mark Kaufmann, Chief Financial Officer, will present an overview of the Company during the Ladenburg Thalmann 2016 Healthcare Conference at 9:30 a.m. Eastern Time on Tuesday, September 27, 2016 at the Sofitel New York Hotel in New York, NY. Paul Korner, MD, MBA, the Company's Executive Vice President and Chief Medical Officer, will also be in attendance.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. In addition to tenapanor, Ardelyx is developing RDX227675, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, a problem prevalent in patients with kidney and heart disease. Ardelyx is also advancing several research programs focused in GI and cardio-renal diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-ladenburg-thalmann-2016-healthcare-conference-300332792.html